KARLI PHILPOT: Open Payments
NPI 1982350609 · CUBA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$455 in 23 payments from 12 companies in 2025. Trend: 2023 $1,404 · 2024 $935 · 2025 $455
Food & beverage: $455
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $137 |
| Lundbeck LLC | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Lilly USA, LLC | 2 | $36 |
| Novo Nordisk Inc | 2 | $34 |
| Dexcom, Inc. | 1 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: REXULTI, QULIPTA, UBRELVY, CAPLYTA, MOUNJARO, Ozempic, Dexcom G6 Transmitter, XIFAXAN.
Industry payments across MO — which companies pay providers there.
